Cogent Biosciences Inc. (COGT) Set for Bezuclastinib Launch, Awaiting FDA Approval

Cogent Biosciences Inc. (NASDAQ:COGT) is one of the best cancer stocks to invest in now. On February 17, CEO Andrew Robbins reiterated that Cogent Biosciences Inc. (NASDAQ:COGT) has started 2026 with tremendous momentum backed by multiple value-creating regulatory catalysts.

In January, the US Food and Drug Administration accepted the company’s PEAK New Drug Application for bezuclastinib in patients with Gastrointestinal Stromal Tumors (GIST). Consequently, the company submitted to the FDA, having already secured Breakthrough Therapy Designation.

The slate of positive regulatory milestones comes on the candidate drug showing clear clinical benefit across all symptom domains. Cogent Biosciences is on the cusp of launching bezuclastinib in the second half of 2026, awaiting FDA approval.

Six Abstracts from the SUMMIT trial of bezuclastinib in patients with Non-Advanced Systemic Mastocytosis (NonAdvSM) have already been accepted for presentation at the 2026 AAAAI annual meeting.

Cogent Biosciences exited 2025 with $900.8 million in cash equivalents and marketable securities, having repaid $54.8 million of long-term debt in the fourth quarter. Research and development expenses increased to $75.6 million in the fourth quarter of 2025 from $62 million in the fourth quarter of 2024.

On the other hand, full-year R&D totaled $269.8 million, up from $232.7 million in 2024. Net loss widened to $102.5 million in the fourth quarter and to $328.9 million for the full year 2025, compared to $67.9 million and $255.9 million for the fourth quarter and full year 2024, respectively .

Cogent Biosciences Inc. (NASDAQ:COGT) is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases. Their primary drug candidate, bezuclastinib (CGT9486), is a potent, selective inhibitor designed to treat systemic mastocytosis and advanced gastrointestinal stromal tumors (GIST) by targeting the KIT D816V mutation.

While we acknowledge the potential of COGT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Manufacturing Stocks to Invest In Now and 11 AI Stocks That Will Go to the Moon.

Disclosure: None.  Follow Insider Monkey on Google News.